

Appl. No. 09/848,249
Reply to Office action of June 5, 2003

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A composition comprising:
a quinoxaline component, and
a fatty acid component, the fatty acid component being present in a complex with the ~~alpha-2-adrenergic agonist quinoxaline component~~; the complex remaining substantially intact in an aqueous environment and the fatty acid component being present in an amount effective to enhance movement of the quinoxaline component across a lipid membrane, and to reduce at least one undesirable side effect when the composition is administered to a patient relative to a substantially identical composition including a quinoxaline component without a fatty acid component.
2. (Currently amended) A composition of claim 1 wherein the fatty acid component is present in an amount effective to enhance the efficacy of the agonist quinoxaline component relative to the efficacy of the ~~alpha-2-adrenergic agonist quinoxaline component~~ without the fatty acid component.
3. (Cancelled)
4. (Previously presented) A composition of claim 1 wherein the quinoxaline component is selected from the group consisting of quinoxaline, (2-imidazolin-2-ylamino) quinoxaline,

Appl. No. 09/848,249
Reply to Office action of June 5, 2003

5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, and derivatives thereof and mixtures thereof.

5. (Original) A composition of claim 1 wherein the fatty acid component is selected from the group consisting of saturated fatty acids and unsaturated fatty acids, derivatives thereof and mixtures thereof.

6. (Original) A composition of claim 1 wherein the fatty acid component is selected from the group consisting of fatty acids having about 12 to about 26 carbon atoms per molecule, derivatives thereof and mixtures thereof.

7. (Original) A composition of claim 1 wherein the fatty acid component is selected from the group consisting of docosahexanoic acids, derivatives thereof and mixtures thereof.

8. (Original) A composition of claim 1 wherein the fatty acid component is selected from the group consisting of linolenic acids, derivatives thereof and mixtures thereof.

9. (Original) A composition of claim 1 wherein the fatty acid component has a therapeutic effect.

10. (Currently amended) A composition of claim 1 wherein the fatty acid component has a therapeutic effect while being in a complex with the agonist quinoxaline component.

11. (Currently amended) A composition of claim 1 wherein the fatty acid component has a therapeutic effect while not being in a complex with the agonist quinoxaline component.

Appl. No. 09/848,249
Reply to Office action of June 5, 2003

12. (Original) A composition of claim 1 wherein the fatty acid component is effective to reduce intraocular pressure when it is administered to the eye.

13. (Original) A composition of claim 1 wherein the fatty acid component is selected from the group consisting of prostanooids, derivatives thereof and mixtures thereof.

14. (Cancelled)

15. (Currently amended) A composition of claim 1 wherein the fatty acid component enhances the movement of the agonist quinoxaline component across a biological membrane under physiological conditions.

16. (Currently amended) A composition of claim 1 wherein the fatty acid component is effective to enhance the therapeutic effect provided by the agonist quinoxaline component.

17. (Original) A composition of claim 1 wherein the complex is able to disassociate in a biological environment.

18. (Currently amended) A composition of claim 1 which includes at least one additional agonist and the fatty acid is complexed with both the agonist quinoxaline component and the additional agonist.

19. (Currently amended) A composition of claim 1 which includes at least one additional fatty acid component and the

Appl. No. 09/848,249
Reply to Office action of June 5, 2003

against quinoxaline component is complexed with both the fatty acid component and the additional fatty acid component.

20. (Original) A composition of claim 1 which is ophthalmically acceptable.

21. (Original) A composition of claim 1 which further comprises a carrier.

22. (Currently amended) A composition of claim 1 wherein the against quinoxaline component comprises 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline; and

the fatty acid component is selected from the group consisting of docosahexanoic acids, linolenic acids, prostanooids, derivatives thereof and mixtures thereof.

23. (Currently amended) A composition comprising:
5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline; and
a linoleic acid component,
wherein the 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline is present in a complex with the linoleic acid component, the complex substantially remains intact in an aqueous environment and the linoleic acid component being present in an amount effective to enhance movement of the 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline across a lipid membrane, and to reduce at least one undesirable side effect when the composition is administered to a patient relative to a substantially identical composition including 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline without a fatty acid component.

Appl. No. 09/848,249
Reply to Office action f June 5, 2003

24. (New) A composition comprising:
a quinoxaline component,
at least one additional agonist, and
a fatty acid component, the fatty acid component being present in a complex with the quinoxaline component and the at least one additional agonist; the complex remaining substantially intact in an aqueous environment and the fatty acid component being present in an amount effective to enhance movement of the quinoxaline component across a lipid membrane relative to a substantially identical quinoxaline component without a fatty acid component.
25. (New) A composition comprising:
a quinoxaline component, and
at least two fatty acid components, the at least two fatty acid components being present in a complex with the quinoxaline component and the at least one additional agonist; the complex remaining substantially intact in an aqueous environment and the fatty acid component being present in an amount effective to enhance movement of the quinoxaline component across a lipid membrane relative to a substantially identical quinoxaline component without a fatty acid component.